Intellia Therapeutics stands on the brink of a potential FDA approval of lonvoguran ziclumeran (lonvo-z; NTLA-2002), a one-time in vivo CRISPR gene-editing therapy for hereditary angioedema (HAE), expected in March 2027. The therapy aims to permanently lower kallikrein and bradykinin levels by inactivating the KLKB1 gene, offering a potential shift from chronic treatments to a single intervention. However, convincing patients already benefiting from existing therapies to opt for an irreversible approach presents a significant commercial challenge.
Market Challenges for a One-Time Therapy
Leonard acknowledged that patients doing well on chronic therapies face recurring treatments, insurance hurdles, and ongoing health concerns. Phase III HAELO study results showed a one-time infusion reduced HAE attacks by 87% versus placebo, with 62% of treated patients remaining attack-free and therapy-free over six months. All patients remained free from long-term prophylaxis through follow-up, with adverse events limited to mild or moderate infusion reactions, headaches, fatigue, and back pain.
Intellia’s market research indicates the burden of HAE extends beyond attacks, driving enrollment in the HAELO trial. Leonard emphasized the company’s focus on providing patients and physicians with full data to guide decisions, with plans to share key metrics around the March 10, 2027 approval timeline.
Liver Toxicity and Nexiguran Program Setbacks
Intellia’s second in vivo CRISPR program, nexiguran ziclumeran (nex-z; NTLA-2001) for TTR amyloidosis, faced clinical holds after a patient in the MAGNITUDE trial experienced Grade 4 liver enzyme elevations and died from complications including sepsis. The FDA paused trials in October 2025, prompting protocol amendments.
Read Also: Enzyme FAH may predict CDK4/6 inhibitor resistance in breast cancer
Clinical holds were lifted in January for MAGNITUDE-2 (ATTRv-PN) and in March for MAGNITUDE (ATTR-CM). New measures exclude high-risk patients and mandate enhanced liver monitoring with short-term steroid guidance. Collaborative genomic analysis with Regeneron identified a specific HLA allele linked to raised transaminases in over 600 patients, offering a predictive tool for risk stratification. The MAGNITUDE trial specifically excludes enrollment of patients who may be most susceptible to potential liver injury, have a recent history of cardiovascular instability, or an ejection fraction <25% at the time of screening. These safeguards aim to proactively identify and mitigate risks before treatment initiation.
Genomic Insights Mitigating Liver Risks in ATTR Trials
The MAGNITUDE trial’s clinical hold stemmed from a fatal case of Grade 4 liver transaminase elevation in a patient with ATTR-CM who later died from sepsis linked to a perforated duodenal ulcer. Collaborating with Regeneron, Intellia sequenced over 600 patient samples to identify a specific HLA allele associated with severe liver enzyme increases. This finding explains previous signals and enables pre-screening to prevent toxicity. HLA genotyping is now provided to all trial participants and investigators to refine eligibility criteria.
Strategic Pipeline Restructuring Post-Approval
Leonard outlined plans to reconfigure Intellia’s pipeline after lonvoguran ziclumeran’s anticipated March 2027 approval. The company will prioritize late-stage programs while evaluating new in vivo editing initiatives based on delivery mechanism compatibility and commercial viability. Research projects leveraging CRISPR platforms remain active, though specific details are withheld until development milestones are met. The firm will apply lessons from its clinical successes and setbacks to assess future candidates.
